R&D News | pharmaphorum

News

Eli Lilly's relentless pipeline-building drive has continued with a licensing deal for Hanmi's sonefpeglutide, in phase 2 for short bowel syndrome.

News

Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.

News

ASCO today brings good news for patients with localised prostate cancer, as early use of J&J's ARPI offers a 19 month increase in median survival.

News

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.

News

Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.